MANA-312 / MANA Therap - LARVOL DELTA

Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT (clinicaltrials.gov) - P1 | N=11 | Terminated | Sponsor: Mana Therapeutics | N=27 ➔ 11 | Active, not recruiting ➔ Terminated; Product manufacturing

Enrollment change • Trial termination • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT (clinicaltrials.gov) - P1 | N=27 | Active, not recruiting | Sponsor: Mana Therapeutics | Trial completion date: Dec 2022 ➔ Mar 2023 | Trial primary completion date: Dec 2022 ➔ Mar 2023

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT (clinicaltrials.gov) - P1 | N=27 | Active, not recruiting | Sponsor: Mana Therapeutics | Recruiting ➔ Active, not recruiting | Trial primary completion date: Jan 2022 ➔ Dec 2022

Enrollment closed • Trial primary completion date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

MANA Therapeutics Announces Final Closing of Series A and Closing of Venture Debt Facility (Businesswire) - "Financing to be used to advance MANA-312 and MANA-412...This is encouraging progress and the data we are collecting will inform the development of our off-the-shelf programs, including MANA-412, which is expected to advance into clinical trials in 2022..."

Commercial • New trial • Oncology

Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT (clinicaltrials.gov) - P1; N=27; Recruiting; Sponsor: Mana Therapeutics; Trial completion date: Sep 2022 ➔ Dec 2022; Trial primary completion date: Sep 2021 ➔ Jan 2022

Clinical • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

MANA Therapeutics Launches with $35 Million Series A Financing (Businesswire) - "Financing to support the MANA-312 Phase 1 study, now underway in patients with AML/MDS after allogeneic HSCT, and accelerate preclinical development of off-the-shelf allogeneic programs...'MANA-412, for which we plan to file an IND in late-2021.'"

Financing • IND • Trial status • Acute Myelogenous Leukemia • Hematological Malignancies • Myelodysplastic Syndrome • Oncology • Solid Tumor